2020-2027 Analysis and Review Oral Ulcer Drug Market
Oral Ulcer Drug Market by Drug Class (Antihistamine, Antimicrobial, Analgesic, Corticosteroid and Others) by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027
The oral ulcer drug market was valued at USD 984.8 Mn by 2019. Rising prevalence of oral infection primarily drives the oral ulcer drug market growth. Furthermore, the flourishing persona care and consumer healthcare segment across the globe further accentuates the market growth.
As per the latest research findings postulated by the International Dental Association (IDA), the major factors responsible for the occurrence of oral ulcers attrition with sharp teeth, accidental biting of the inside of your cheek, poor oral hygiene, and burns from eating hot food. The presence of mucosal irritants such as tobacco products, betel nuts for a longer period of time can aggravate the occurrence of painful mouth lesions. Positive marketing strategy to educate consumers worldwide pertaining to the importance of oral health & hygiene and increasing disposable income in low and middle-income countries further propels the oral ulcer drug market growth.
The major segments related to the oral ulcer drug market are:
By Drug Class (2017–2027; US$ Mn)
Antihistamine
Antimicrobial
Analgesic
Corticosteroid
Others
By Distribution Channel (2017–2027; US$ Mn)
Hospital Pharmacy
Retail Pharmacy
Others
Geography Segment (2017–2027; US$ Mn)
North America
U.S.
Canada
Europe
United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of Latin America
Middle East and Africa (MEA)
GCC
Rest of MEA
Justification for study?
Report gist?
The study includes the profiles of major market players with a significant global and regional presence along with top company positioning.
Significant customers?
Segment Analysis
Analgesics are currently dominating the drug class market for the oral ulcer drugs market. A significant increase in the number of individuals suffering from aphthous ulcers has led to the increasing demand for analgesics to relieve the excruciating pain the most widely preferred analgesics for the treatment of oral ulcers are lignocaine hydrochloride, benzocaine, etc. Corticosteroids will be highlighting exemplary market performance in the near future on account of its anti-inflammatory properties in the treatment of canker sores. The corticosteroids used in drug formulation for the treatment of oral ulcers are Hydrocortisone hemisuccinate, Triamcinolone acetonide, and Betamethasone sodium phosphate.
Hospital pharmacy is representing the largest market share in the oral ulcer drug market. The majority of drug formulations intending for the treatment of oral infections contain schedule H and schedule X drugs which need to be taken under the medical supervision of a hospital pharmacist. Retail pharmacy is expected to highlight sturdy market growth during the forecast period owing to the flourishing personal and consumer care products and the provision of essential medicines at a low price.
North America is currently leading the geography segment for the oral ulcer drug market. The growing incidence of oral infection primarily drives the market growth of oral ulcer drugs in the region. According to the latest statistics provided by the Center for Disease Control and Prevention (CDC), the prevalence rate associated with oral ulceration in the United States is 4%. Furthermore, the favorable reimbursement scenario associated with the oral ulcer drugs and domicile of key players in the region such as 3M Company, Reckitt Benckiser, Colgate-Palmolive Company, Church & Dwight Co, Inc., etc., further accentuates the market growth in the region. Europe is considered as the second-largest regional segment for the oral ulcer drug market owing to the nurturing regulatory environment provided by the European Medical Agency (EMA), for the sale and distribution of oral ulcer drugs in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for oral ulcer drugs market on account of the rising prevalence of oral infection due to poor hygiene, chewing of tobacco, betel nuts, etc., and flourishing personal and consumer healthcare segment.
$4,600 | |
$6,600 | |
$13,200 |
Request customization |
Get market alerts |
Ask for regional data |
Ask for country-specific data |